Millions of Americans took compounded semaglutide or tirzepatide over the past two years. Most of them have never thought about the legal framework that made it available — or the regulatory changes that are reshaping it. Understanding compounding law helps patients ask better questions, evaluate their options, and recognize when something may be off.
What Is Pharmaceutical Compounding?
Pharmaceutical compounding is the preparation of a customized medication for an individual patient when a commercially available product does not meet that patient's specific needs. It is one of the oldest practices in pharmacy — before mass manufacturing, virtually all medications were compounded by the local pharmacist to suit the individual.
Traditional examples of legitimate compounding include removing an allergen from a commercial formulation, creating a liquid version of a pill for a patient who cannot swallow tablets, or producing a pediatric dose of a drug that is only commercially available in adult-strength forms. Each of these involves a genuine patient-specific need that a commercially available drug cannot satisfy.
What compounding is not: it is not generic drug manufacturing, and compounders cannot legally mass-produce copies of FDA-approved drugs for general distribution. The statutory and regulatory prohibition on "essentially a copy" of an FDA-approved drug is one of the central legal constraints on the industry. When compounders cross this line — producing large volumes of commercial-equivalent formulations without a recognized exception — they expose themselves to FDA enforcement action.
The key legal requirements depend on the type of compounding facility. For a 503A pharmacy (the most common type), a valid patient-specific prescription must exist before compounding begins. For a 503B outsourcing facility, a different set of rules applies — but federal oversight is meaningfully stricter.
The Two Types of Compounding Pharmacies
Federal law currently recognizes two pathways for pharmaceutical compounding, each with distinct requirements, oversight structures, and permitted activities. Understanding the difference is one of the most practically useful things a GLP-1 patient can know.
503A Pharmacies
Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding pharmacies — the state-licensed facilities that prepare customized medications for individual patients. Most compounding pharmacies in the United States operate under 503A.
- Prescription requirement: A 503A pharmacy must have a valid, patient-specific prescription before compounding a drug. The prescription must come from a licensed practitioner with a legitimate patient-prescriber relationship.
- State-regulated: 503A pharmacies are primarily overseen by state pharmacy boards, not the FDA. The FDA's Center for Drug Evaluation and Research (CDER) has limited direct enforcement authority over routine 503A compounding activity, though it retains authority in cases involving safety threats or violations of federal law.
- Cannot sell to the general public in bulk: A 503A pharmacy cannot legally advertise compounded preparations to the general public or distribute them wholesale. The prescription must be patient-specific.
- Inconsistent quality oversight: Because state pharmacy board oversight varies significantly in rigor and resources, the quality practices of 503A pharmacies are not uniform. Some are meticulous; others are not. There is no federal cGMP requirement for 503A facilities.
- The practical implication: When you receive a compounded GLP-1 medication through a telehealth platform or prescribing program, that prescription is likely being filled by a 503A pharmacy. The quality of that pharmacy is not guaranteed by the telehealth platform's brand.
503B Outsourcing Facilities
Section 503B was created by the Drug Quality and Security Act of 2013 (DQSA), enacted in the aftermath of a 2012 fungal meningitis outbreak caused by contaminated medications from a compounding pharmacy that was operating far outside appropriate standards. 503B was Congress's answer: create a higher-tier, federally registered pathway for larger-scale compounding with meaningful quality requirements.
- Voluntary FDA registration: 503B outsourcing facilities voluntarily register with the FDA — they are not required to, but registration affords them certain benefits including the ability to compound without individual patient prescriptions.
- Subject to cGMP: 503B facilities must comply with current Good Manufacturing Practice (cGMP) standards — the same quality manufacturing standards applied to pharmaceutical manufacturers. This means validated processes, environmental monitoring, and systematic quality control.
- Can produce larger batches: Unlike 503A pharmacies, 503B facilities can produce batches of compounded drugs without patient-specific prescriptions, for distribution to healthcare facilities and practitioners.
- FDA inspects regularly: FDA conducts inspections of 503B facilities and has issued warning letters and initiated shutdowns of facilities that failed to meet cGMP standards. The enforcement record is public.
- Public list available: FDA maintains a public list of registered 503B outsourcing facilities on its website. If a pharmacy claims 503B status, that claim is verifiable.
- Generally the higher standard: For patients seeking compounded GLP-1 medications, a 503B outsourcing facility represents the higher quality assurance tier. The cGMP requirement and federal inspection regime provide meaningful structural safeguards that 503A pharmacies are not subject to.
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Primary regulator | State pharmacy board | FDA (federal) |
| Prescription required? | Yes — patient-specific before compounding | Not required (can compound for healthcare facilities) |
| cGMP standards | No federal cGMP requirement | Yes — required |
| FDA inspections | Limited | Regular; warning letters/shutdowns on record |
| Batch size | Limited — patient-specific | Larger batches permitted |
| Publicly registered? | No federal registry | Yes — FDA maintains public list |
| Quality consistency | Highly variable by state and facility | More consistent; federally audited |
The Drug Shortage Exception — How Compounded GLP-1s Became Legal
Both Section 503A and Section 503B include statutory provisions that allow compounding of a drug that appears on the FDA's official drug shortage list. This exception was the legal engine behind the explosion of compounded GLP-1 medications in 2022–2024.
The prohibition on compounding "essentially a copy" of an FDA-approved drug is lifted when that drug is on the shortage list. The logic is straightforward: if patients cannot access the approved drug because supply is inadequate, compounders can fill the gap. The public health interest in patient access overrides, temporarily, the competitive and safety policy rationale for the copy prohibition.
Ozempic (semaglutide for diabetes), Wegovy (semaglutide for weight management), Mounjaro (tirzepatide for diabetes), and Zepbound (tirzepatide for weight management) all appeared on the FDA drug shortage list during 2022–2024. The cause was a combination that the pharmaceutical supply chain was not designed to handle: an existing patient population dependent on these medications for blood sugar management, plus an enormous and rapidly growing demand from patients using the same drugs for weight loss. Manufacturers could not scale production fast enough.
While each of these drugs remained on the shortage list, compounders — both 503A pharmacies and 503B outsourcing facilities — could legally prepare versions of them. This is the statutory basis on which thousands of programs began offering compounded semaglutide and tirzepatide at prices significantly below the branded alternatives. It was not a regulatory loophole in the pejorative sense; it was an explicit statutory provision functioning as intended.
What Changed in 2024–2026
The drug shortage exception has a defined duration: it applies while a drug is on the shortage list. Once FDA makes a determination that a shortage has resolved and removes the drug from the list, the exception ceases to apply. This is where the regulatory picture changed dramatically for GLP-1 medications.
Semaglutide Shortage Resolved
In early 2025, FDA removed Ozempic and Wegovy from the drug shortage list, finding that the shortage had resolved. This determination was contested by some in the compounding industry, who argued that access remained inadequate, but FDA's regulatory conclusion controlled the legal outcome.
Once removed from the list, the shortage exception was no longer available to 503B outsourcing facilities. They could no longer legally bulk-compound copies of semaglutide formulations. FDA issued guidance making this position explicit, and subsequently initiated enforcement actions against 503B facilities that continued compounding after the removal date.
For 503A pharmacies, the picture became more complex. Some argued that 503A pharmacies have narrower but continued authority to compound semaglutide on patient-specific individualized grounds — particularly where a patient has a documented need that the commercial product cannot satisfy (such as a specific dose not commercially available, or a documented allergy to an inactive ingredient). This position is legally contested and has been the subject of litigation from compounders challenging FDA's enforcement posture.
The practical bottom line: compounded semaglutide availability has narrowed significantly. Many programs that offered it no longer do, or have pivoted to tirzepatide. The market that existed in 2023–2024 looks materially different as of 2026.
Tirzepatide Evolving — Verify Current Status
Mounjaro and Zepbound remained on the drug shortage list longer than the semaglutide products. As of mid-2026, tirzepatide compounding remains available through many 503A pharmacies and some 503B facilities — the shortage exception still applies while tirzepatide products remain on the list.
However, FDA has signaled attention to the tirzepatide compounding space, and the regulatory status could change with FDA's next shortage list determination. Patients and prescribers seeking compounded tirzepatide should verify the current shortage list status at the time they seek a prescription. Availability that exists today may not exist in six months.
The Semaglutide Base vs. Salt Issue
A separate legal and scientific dispute emerged in parallel with the shortage resolution debate — one that goes to the chemistry of what was actually being compounded.
Ozempic and Wegovy use semaglutide in its base form. Some compounding pharmacies and their suppliers were sourcing and using semaglutide sodium — a salt form of semaglutide in which the molecule is associated with a sodium ion. Some compounders argued that semaglutide sodium is technically a different chemical compound, not the same as the semaglutide in Ozempic, and therefore not subject to the copy prohibition even after the shortage list removal.
FDA rejected this argument. The agency took the position that semaglutide sodium is a salt form of semaglutide — and that the copy prohibition applies to the active ingredient, not its salt form. Under established pharmaceutical science and FDA regulatory practice, a drug and its salt forms are treated as the same active ingredient for approval and regulatory purposes. The distinction compounders were drawing, FDA concluded, did not represent the kind of meaningful pharmacological difference that would justify treating the compounds separately.
The debate has both legal and scientific dimensions, and litigation is ongoing. Some compounders continue to litigate this position; FDA's enforcement posture remains that semaglutide sodium does not escape the copy prohibition.
The practical implication for patients: if your compounder represents that they are using "semaglutide sodium" to distinguish their product from the Ozempic/Wegovy prohibition, understand that FDA has explicitly rejected the legal basis for that distinction. Ask specifically what form the compounder uses, and ask your prescriber or a pharmacist to evaluate the answer.
→ Related: Semaglutide Base vs. Acetate/Sodium Salt: The Science, the FDA's Position, and the Compounders' Argument — a full deep dive into the chemistry question, the clinical equivalence debate, and where the litigation stands.
What "Added Ingredients" Mean Legally
Walk through enough compounding pharmacy offerings and you will encounter formulations that include semaglutide or tirzepatide alongside additional ingredients — vitamin B12 is common, as are NAD+, L-carnitine, and various other compounds. The marketing often positions these as enhancements. The legal and clinical picture is more complicated.
The legal analysis
Under 503A rules, a compounder can add ingredients to a preparation if there is a valid clinical reason specific to that patient. The key word is specific: the added ingredient should serve an individualized therapeutic purpose for the particular patient, documented in the prescription, not serve as a general commercial differentiator applied to every customer regardless of individual need.
The legal risk is this: adding ingredients primarily to create a formulation that is technically "different" from the FDA-approved drug — to argue that the preparation is not "essentially a copy" and therefore not subject to the copy prohibition — is a contested legal strategy. FDA has been skeptical of this approach, viewing it as an attempt to circumvent the prohibition through superficial modification rather than genuine patient-specific individualization. Whether the added ingredient provides genuine individualized therapeutic benefit, or is being used primarily to manufacture a legal distinction, is a question FDA has examined closely.
The clinical analysis
Added ingredients also create independent safety and quality considerations. The GLP-1 mechanism is well understood; the clinical rationale for co-administering B12 with semaglutide or tirzepatide in every patient is not established by controlled trial evidence. Some added ingredients may be unnecessary. Some may have interactions or contraindications in specific patient populations. The Certificate of Analysis from third-party testing should cover every ingredient in the formulation — not just the active molecule.
What Patients Should Know
The regulatory complexity of pharmaceutical compounding is not abstract — it affects the safety, legality, and continued availability of the medications patients are using. The following points are the ones that matter most practically.
- Your medication is not FDA-approved. Compounded drugs bypass the FDA drug approval process by definition. They have not undergone the clinical trials and manufacturing review that branded medications undergo. This is not necessarily disqualifying, but it is a material fact.
- The shortage exception has a shelf life. The legal availability of compounded GLP-1 medications depends on the drug shortage list. When a drug leaves the list, the primary legal basis for compounding it changes — often significantly. Your program's legal standing may shift without your being notified.
- Quality is not uniform across pharmacies. A 503B outsourcing facility subject to federal cGMP standards and regular FDA inspection offers meaningfully stronger quality assurance than an unaudited 503A pharmacy. Ask which designation your pharmacy holds — and verify it on FDA's public registry.
- A valid prescription is legally required. Whether you are working with a 503A pharmacy (patient-specific prescription required before compounding) or a 503B facility (prescription required for dispensing to you), you must have a legitimate prescription from a licensed prescriber with whom you have a genuine clinical relationship. No prescription is a significant red flag.
- Price reflects more than ingredient cost. Compounding costs vary significantly. A 503B facility with cGMP compliance, third-party CoA testing, and rigorous quality control will cost more than a 503A pharmacy with minimal oversight. Price differences reflect real differences in quality infrastructure — not just markup.